---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-032851"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2026-07-10T20:30:31+00:00"
generated_at: "2026-07-10T20:31:13.244303+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ZyVersa Therapeutics explores cost cuts, potential going dark, and asset sales; director Park resigns

## Summary
- Director Min Chul Park resigned effective July 8, 2026, for personal reasons, no disagreement with company.
- CEO Stephen Glover and CFO Peter Wolfe voluntarily accepted reduced compensation to preserve cash.
- Company considering divesting VAR 200 or IC 100 product candidates and reducing headcount.
- Company may go dark by suspending SEC reporting obligations under Rule 12h-3.
- Also evaluating sale of company or assets, restructuring, or reorganization to maximize shareholder value.

## SEC filing metadata
- accession: 0001493152-26-032851
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2026-07-10T20:30:31+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315226032851/0001493152-26-032851-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315226032851/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-032851
- JSON: https://secwatch.observer/filing/0001493152-26-032851.json
- Plain text: https://secwatch.observer/filing/0001493152-26-032851.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.